211 related articles for article (PubMed ID: 25371066)
1. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.
Valent P; Sadovnik I; Ráčil Z; Herrmann H; Blatt K; Cerny-Reiterer S; Eisenwort G; Lion T; Holyoake T; Mayer J
Eur J Clin Invest; 2014 Dec; 44(12):1239-45. PubMed ID: 25371066
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
[TBL] [Abstract][Full Text] [Related]
3. Flow Cytometry Assessment of CD26
Raspadori D; Pacelli P; Sicuranza A; Abruzzese E; Iurlo A; Cattaneo D; Gozzini A; Galimberti S; Baratè C; Pregno P; Nicolosi M; Sorà F; Annunziata M; Luciano L; Caocci G; Moretti S; Sgherza N; Fozza C; Russo S; Usala E; Liberati MA; Ciofini S; Trawinska MM; Gozzetti A; Bocchia M
Cytometry B Clin Cytom; 2019 Jul; 96(4):294-299. PubMed ID: 30714299
[TBL] [Abstract][Full Text] [Related]
4. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
5. Phenotyping and Target Expression Profiling of CD34
Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
[TBL] [Abstract][Full Text] [Related]
6. Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia.
Sharma P; Sachdeva MUS; Naseem S; Sreedharanunni S; Das R; Malhotra P; Varma N
Int J Lab Hematol; 2022 Jun; 44(3):518-523. PubMed ID: 35142061
[TBL] [Abstract][Full Text] [Related]
7. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
8. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
Mustjoki S; Richter J; Barbany G; Ehrencrona H; Fioretos T; Gedde-Dahl T; Gjertsen BT; Hovland R; Hernesniemi S; Josefsen D; Koskenvesa P; Dybedal I; Markevärn B; Olofsson T; Olsson-Strömberg U; Rapakko K; Thunberg S; Stenke L; Simonsson B; Porkka K; Hjorth-Hansen H;
Leukemia; 2013 Jul; 27(7):1520-6. PubMed ID: 23328954
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.
Culen M; Borsky M; Nemethova V; Razga F; Smejkal J; Jurcek T; Dvorakova D; Zackova D; Weinbergerova B; Semerad L; Sadovnik I; Eisenwort G; Herrmann H; Valent P; Mayer J; Racil Z
Oncotarget; 2016 May; 7(22):33016-24. PubMed ID: 27145281
[TBL] [Abstract][Full Text] [Related]
10. CD26 expression on circulating CD34+/CD38- progenitor population is a specific and reliable tool for the rapid flow cytometric diagnosis of chronic myeloid leukemia-A single-center validation study.
Rahman K; Singh MK; Chandra D; Gupta R; Sarkar MK; Gupta P; Gupta A; Yadav S; Kashyap R; Nityanand S
Int J Lab Hematol; 2022 Jun; 44(3):524-530. PubMed ID: 35315228
[TBL] [Abstract][Full Text] [Related]
11. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract][Full Text] [Related]
12. Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.
Thielen N; Richter J; Baldauf M; Barbany G; Fioretos T; Giles F; Gjertsen BT; Hochhaus A; Schuurhuis GJ; Sopper S; Stenke L; Thunberg S; Wolf D; Ossenkoppele G; Porkka K; Janssen J; Mustjoki S
Clin Cancer Res; 2016 Aug; 22(16):4030-8. PubMed ID: 27006491
[TBL] [Abstract][Full Text] [Related]
13. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia.
Stoklosa T; Glodkowska-Mrowka E; Hoser G; Kielak M; Seferynska I; Wlodarski P
Exp Hematol; 2013 May; 41(5):462-9. PubMed ID: 23395818
[TBL] [Abstract][Full Text] [Related]
14. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
15. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
Warfvinge R; Geironson L; Sommarin MNE; Lang S; Karlsson C; Roschupkina T; Stenke L; Stentoft J; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S; Soneji S; Richter J; Karlsson G
Blood; 2017 Apr; 129(17):2384-2394. PubMed ID: 28122740
[TBL] [Abstract][Full Text] [Related]
16. The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Chen Y; Li D; Li S
Cell Cycle; 2009 Nov; 8(21):3488-92. PubMed ID: 19823023
[TBL] [Abstract][Full Text] [Related]
17. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.
Janssen JJ; Deenik W; Smolders KG; van Kuijk BJ; Pouwels W; Kelder A; Cornelissen JJ; Schuurhuis GJ; Ossenkoppele GJ
Leukemia; 2012 May; 26(5):977-84. PubMed ID: 22157734
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing CML LSCs from HSCs using CD26.
Jiang X
Blood; 2014 Jun; 123(25):3851-2. PubMed ID: 24948622
[TBL] [Abstract][Full Text] [Related]
19. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
Valent P
Br J Haematol; 2008 Jul; 142(3):361-78. PubMed ID: 18540942
[TBL] [Abstract][Full Text] [Related]
20. miRNome profiling of LSC-enriched CD34
Ruiz MS; Sánchez MB; Bonecker S; Furtado C; Koile D; Yankilevich P; Cranco S; Custidiano MDR; Freitas J; Moiraghi B; Pérez MA; Pavlovsky C; Varela AI; Ventriglia V; Sánchez Ávalos JC; Larripa I; Zalcberg I; Mordoh J; Valent P; Bianchini M
Front Pharmacol; 2020; 11():612573. PubMed ID: 33569005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
